Infectious diseases move quickly, and it can be particularly difficult to predict when and where an emerging infectious disease (EID) outbreak will occur. This poses a challenge for vaccine efficacy trials, which hinge upon active transmission of the target disease in a population to gather meaningful data. As a result, effective disease surveillance is a critical element to support vaccine development.
Early detection of EIDs through global disease surveillance allows researchers to begin developing vaccines as soon as possible and minimise the impact of the disease. Disease surveillance can also inform vaccine trials on where an EID is prevalent so that it can be tested in a relevant population. Because infectious diseases can move quickly, disease surveillance is a key element in vaccine efficacy trials. As a result, understanding current approaches to disease surveillance early alert systems is a helpful tool for advancing EID vaccine development.
Early alert systems
Early alert systems can play a critical role in the quick response to an outbreak. These alerts advise researchers on appropriate site selection and when to initiate vaccine trials. The earlier a disease is detected in a population, the sooner and more efficiently the response can be mobilised.
Early warning strategies involve the use of environmental observations, such as extremely rainy weather, which are associated with outbreaks of a specific disease. However, when a disease is new or uncommon, these measures may have limited effectiveness given there might not be enough information available to fully utilise them. Alternatively, surveillance of agricultural, farm and virology workers, particularly genetic testing when ill workers test negative for most common illnesses in their region, may be particularly effective as these individuals are most likely to be exposed to new and emerging pathogens.1
In an effort to establish early alert systems, the African Center of Excellence for Genomics and Infectious Disease (ACEGID) and the Broad Institute have teamed up for the Sentinel project.2 Based on three pillars – Detect, Connect and Empower – this early warning system is meant to use genomics and information technologies to detect viral threats early and enable public health systems to respond quickly. This is not ACEGID’s only experience with early detection of disease, either, as it has long been committed to studying and responding to infectious disease. For instance, the organisation identified a new yellow fever outbreak in Nigeria in 2018 through the use of real-time microbial metagenomics.3
Wastewater Surveillance
Disease surveillance often depends on individuals seeing a physician when they feel ill. However, medical attention is not always an option for people due to the expense, lack of access and potential distrust of the healthcare system. The question remains: How do we detect the presence of an EID in a population as early as possible?
Wastewater surveillance may offer a compelling answer. It was first widely implemented in the detection of SARS-CoV-2 but now shows great promise with other diseases. Because many pathogens are shed from the body in stool and other waste, analysing wastewater can provide numerous helpful insights regarding the presence of an EID in a community. This method does not depend on individually testing everyone who is ill to get an accurate picture of the prevalence of a particular EID. Additionally, it can detect the presence of a pathogen before patients develop symptoms or if they are asymptomatic carriers of diseases. Such advanced knowledge provides researchers ample time to mobilise vaccine trials while an area is still being impacted by an EID so that as much relevant data can be gathered as possible.
Preparing for the future
While emerging infectious diseases may be difficult to predict, there is much that sponsors and researchers can do now to prepare for new outbreaks that may threaten public health. Methods such as pre-emptive vaccine research, disease surveillance and strategic vaccine trial design can help to fortify vaccine development and the necessary accompanying infrastructure.
To learn more about the use of disease surveillance and reporting in vaccine development, read the whitepaper, ‘Fortifying vaccines: Preparation and prevention against future infectious disease epidemics’.
References:
- Maxmen, Amy. “Has COVID Taught Us Anything about Pandemic Preparedness?” Nature, vol. 596, no. 7872, Aug. 2021, pp. 332–35.
- ACEGID + Broad Institute | The Audacious Project. Accessed 17 Oct. 2022.
- Ajogbasile, Fehintola V., et al. “Real-Time Metagenomic Analysis of Undiagnosed Fever Cases Unveils a Yellow Fever Outbreak in Edo State, Nigeria.” Scientific Reports, vol. 10, no. 1, 2020, p. 3180.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel